GPT and HIV-1 infection: In landmark trials, “Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1” (DRIVE-FORWARD), “Doravirine/lamivudine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naïve adults with HIV-1 infection” (DRIVE-AHEAD), and “Switching to doravirine/lamivudine/tenofovir disoproxil fumarate maintains HIV-1 virologic suppression” (DRIVE-SHIFT), ALT elevations above five times the upper limit of normal (ULN) occurred in less than 2% of patients enrolled and did not require medication discontinuation [16,17,18].